作者: Stefania Beghelli , Giovanni de Manzoni , Stefano Barbi , Anna Tomezzoli , Franco Roviello
DOI: 10.1016/J.SURG.2005.08.021
关键词:
摘要: Background The assessment of microsatellite instability (MSI) is not included yet in the routine evaluation patients with gastric cancer, as controversial data exist regarding its prognostic value. Methods We determined clinical significance MSI 510 sporadic cancers, using mononucleotide markers BAT25 and BAT26. results were compared immunohistochemical expression mismatch repair proteins Mlh1 Msh2. Results was present 83 (16%) cancers correlated better survival (P Conclusions Microsatellite analysis cancer has utility determination prognosis, but should be only stage II neoplasms a setting. Immunohistochemistry may considered sufficient, although preferable.